Apixaban with antiplatelet therapy after acute coronary syndrome.

Published

Journal Article

BACKGROUND: Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome. METHODS: We conducted a randomized, double-blind, placebo-controlled clinical trial comparing apixaban, at a dose of 5 mg twice daily, with placebo, in addition to standard antiplatelet therapy, in patients with a recent acute coronary syndrome and at least two additional risk factors for recurrent ischemic events. RESULTS: The trial was terminated prematurely after recruitment of 7392 patients because of an increase in major bleeding events with apixaban in the absence of a counterbalancing reduction in recurrent ischemic events. With a median follow-up of 241 days, the primary outcome of cardiovascular death, myocardial infarction, or ischemic stroke occurred in 279 of the 3705 patients (7.5%) assigned to apixaban (13.2 events per 100 patient-years) and in 293 of the 3687 patients (7.9%) assigned to placebo (14.0 events per 100 patient-years) (hazard ratio with apixaban, 0.95; 95% confidence interval [CI], 0.80 to 1.11; P=0.51). The primary safety outcome of major bleeding according to the Thrombolysis in Myocardial Infarction (TIMI) definition occurred in 46 of the 3673 patients (1.3%) who received at least one dose of apixaban (2.4 events per 100 patient-years) and in 18 of the 3642 patients (0.5%) who received at least one dose of placebo (0.9 events per 100 patient-years) (hazard ratio with apixaban, 2.59; 95% CI, 1.50 to 4.46; P=0.001). A greater number of intracranial and fatal bleeding events occurred with apixaban than with placebo. CONCLUSIONS: The addition of apixaban, at a dose of 5 mg twice daily, to antiplatelet therapy in high-risk patients after an acute coronary syndrome increased the number of major bleeding events without a significant reduction in recurrent ischemic events. (Funded by Bristol-Myers Squibb and Pfizer; APPRAISE-2 ClinicalTrials.gov number, NCT00831441.).

Full Text

Duke Authors

Cited Authors

  • Alexander, JH; Lopes, RD; James, S; Kilaru, R; He, Y; Mohan, P; Bhatt, DL; Goodman, S; Verheugt, FW; Flather, M; Huber, K; Liaw, D; Husted, SE; Lopez-Sendon, J; De Caterina, R; Jansky, P; Darius, H; Vinereanu, D; Cornel, JH; Cools, F; Atar, D; Leiva-Pons, JL; Keltai, M; Ogawa, H; Pais, P; Parkhomenko, A; Ruzyllo, W; Diaz, R; White, H; Ruda, M; Geraldes, M; Lawrence, J; Harrington, RA; Wallentin, L; APPRAISE-2 Investigators,

Published Date

  • August 25, 2011

Published In

Volume / Issue

  • 365 / 8

Start / End Page

  • 699 - 708

PubMed ID

  • 21780946

Pubmed Central ID

  • 21780946

Electronic International Standard Serial Number (EISSN)

  • 1533-4406

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1105819

Language

  • eng

Conference Location

  • United States